Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy.
Hung YH, Yu AL, Chen YC, Tsai CH, Su MY, Shun CT, Hsueh HW, Jyh-Ming Juang J, Lee MJ, Tseng PH, Hsu CH, Hsieh ST, Ko CL, Lin KP, Yu WC, Cheng MF, Chao CC, Lin YH. Hung YH, et al. Among authors: hsu ch. J Formos Med Assoc. 2024 Oct 10:S0929-6646(24)00481-9. doi: 10.1016/j.jfma.2024.10.005. Online ahead of print. J Formos Med Assoc. 2024. PMID: 39389803 Free article.
Use of Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy.
Yu AL, Chen YC, Tsai CH, Wu YA, Su MY, Chou CH, Shun CT, Hsueh HW, Juang JJ, Lee MJ, Tseng PH, Hsu CH, Hsieh ST, Ko CL, Cheng MF, Chao CC, Lin YH. Yu AL, et al. Among authors: hsu ch. J Am Heart Assoc. 2024 Jan 16;13(2):e030512. doi: 10.1161/JAHA.123.030512. Epub 2024 Jan 12. J Am Heart Assoc. 2024. PMID: 38214277 Free PMC article.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Lancet. 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551-0. Online ahead of print. Lancet. 2025. PMID: 39798579
2,410 results